Press Releases |News

02/11/2021

Tempus Announces the Appointment of Nobel Laureate and CRISPR Co-Inventor, Dr. Jennifer Doudna, to its Board of Directors

Tempus, a leader in artificial intelligence and precision medicine, today announced that Dr. Jennifer Doudna has joined its Board of Directors. Dr. Doudna will serve as an advisor to Tempus and its leadership team, leveraging her vast experience in genomics innovation and research to support Tempus as it leads the way in ap...

02/09/2021

Tempus Launches Hereditary Cancer Germline Assay, xG

Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of its new germline sequencing assay, xG, a 52-gene panel that specifically identifies genetic variants associated with hereditary cancer syndromes and inherited risk of cancer. Tempus xG, which is now available to order, is performed by GeneDx, I...

01/27/2021

Tempus Expands Licensing Agreement with Bristol Myers Squibb to Analyze and Discover RNA-Based Targets

Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of an agreement with Bristol Myers Squibb, in which Tempus delivers de-identified transcriptomic datasets to enhance Bristol Myers Squibb’s research efforts on new biomarkers related to certain cancer subtypes. The agreement also enables rapid access to n...

01/22/2021

Clinical Breast Cancer Study Reveals that Tempus’ Real-World Database Mirrors Overall U.S. Breast Cancer Population

Tempus, a leader in artificial intelligence and precision medicine, announces a recent study in Clinical Breast Cancer that demonstrates how Tempus’ real-world database mirrors the U.S. breast cancer population, ultimately suggesting that real-time, real-world data analyses are feasible in a large, highly heterogeneous database. For the study,...

01/13/2021

Tempus Announces Companion Diagnostic Collaboration with A2 Biotherapeutics

Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to develop a companion diagnostic (CDx) test with A2 Biotherapeutics for its new therapy targeting patients with Loss of Heterozygosity (LOH). It is anticipated that this collaboration could also provide a platform for the...

01/11/2021

Tempus Unveils A Breakthrough in AI for Oncologists: Tempus ONE

Tempus, a leader in AI-enabled diagnostics, today unveiled a breakthrough technology for oncologists, Tempus ONE. This smart, voice-enabled, portable device brings Tempus’ proprietary platform and unparalleled library of multi-modal data to life, offering physicians real-time access to all the clinical insights and data contained in Tempus’ genomic reports...

12/14/2020

Product Launch

Tempus Announces Abdul Hamid Halabi as Senior Vice President of Data Products

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced that Abdul Hamid Halabi has joined as Senior Vice President of Data Products. Abdul has been a pioneer in AI and healthcare, developing key concepts in AI-powered diagnostics and intelligent medical devices and will leverage his...

12/10/2020

Genomic Sequencing

Bayer and Tempus Initiate Collaboration to Advance Patient Access to Genomic Testing and Precision Medicine

Bayer and Tempus, leaders in precision medicine and artificial intelligence (AI), announced a new collaboration designed to provide broader access to genomic testing and tailored treatment approaches for the oncology community. The collaboration will include an initiative to help facilitate patient identification for precision oncology by providing testing, via the Te...

12/10/2020

Cardiology

Tempus Announces $200 Million Series G-2 Financing

Tempus, a leader in artificial intelligence and precision medicine, today announced an additional $200 million financing at a post-money valuation of $8.1 billion dollars, and an additional $250 million of convertible debt. The investors include Baillie Gifford, Franklin Templeton, Google, Novo Holdings, and funds and accounts managed by T. Rowe Price....

11/24/2020

Tempus CE Marks Its Broad-Panel Genomic Sequencing Test, xT

Tempus, a leader in artificial intelligence and precision medicine, today announced that it has CE marked its signature broad-panel genomic sequencing assay, xT. The CE marked xT test is now available for clinical use in Europe. As part of Tempus’ broader regulatory strategy, European clinicians and their patients...

NEWS

Press Releases

Media Coverage

Additional Partnerships

Blog